Skip to Content

ACADIA Pharmaceuticals Inc ACAD

Morningstar Rating
$22.60 +0.32 (1.44%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

ACAD is trading at a 13% discount.
Price
$22.67
Fair Value
$87.36
Uncertainty
Very High
1-Star Price
$27.18
5-Star Price
$26.34
Economic Moat
Sqgns
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ACAD is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$22.28
Day Range
$22.0722.76
52-Week Range
$14.4533.99
Bid/Ask
$22.47 / $22.60
Market Cap
$3.71 Bil
Volume/Avg
1.2 Mil / 1.6 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
5.83
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
580

Valuation

Metric
ACAD
Price/Earnings (Normalized)
Price/Book Value
10.23
Price/Sales
5.83
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
ACAD
Quick Ratio
2.10
Current Ratio
2.38
Interest Coverage
Quick Ratio
ACAD

Profitability

Metric
ACAD
Return on Assets (Normalized)
−16.67%
Return on Equity (Normalized)
−26.56%
Return on Invested Capital (Normalized)
−25.83%
Return on Assets
ACAD

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLpdx$458.6 Bil
VRTX
Vertex Pharmaceuticals IncQtlmtzb$90.5 Bil
REGN
Regeneron Pharmaceuticals IncTstmrk$88.8 Bil
SGEN
Seagen Inc Ordinary SharesYbdxng$40.1 Bil
MRNA
Moderna IncYts$30.4 Bil
ARGX
argenx SE ADRCmf$27.0 Bil
BNTX
BioNTech SE ADRSrtv$23.6 Bil
ALNY
Alnylam Pharmaceuticals IncMbdqc$21.5 Bil
BMRN
Biomarin Pharmaceutical IncBfjbqzd$17.4 Bil
INCY
Incyte CorpHbwpym$12.1 Bil